Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 58, Issue 2, Pages 180-192
Publisher
Wiley
Online
2017-08-11
DOI
10.1002/jcph.988
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
- (2016) Neeraj Gupta et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
- (2016) Neeraj Gupta et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
- (2016) Neeraj Gupta et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decreased Linezolid Serum Concentrations in Three Critically Ill Patients: Clinical Case Studies of a Potential Drug Interaction between Linezolid and Rifampicin
- (2016) Ute Blassmann et al. PHARMACOLOGY
- Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3
- (2015) Wendy P. Battisti et al. ANNALS OF INTERNAL MEDICINE
- Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis
- (2015) Neeraj Gupta et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients
- (2015) Neeraj Gupta et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
- (2015) Neeraj Gupta et al. Journal of Hematology & Oncology
- Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
- (2014) P. G. Richardson et al. BLOOD
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data
- (2013) Fumiyoshi Yamashita et al. PLoS One
- Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections
- (2012) Irma Hoyo et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
- (2010) Francesca Gay et al. AMERICAN JOURNAL OF HEMATOLOGY
- A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development
- (2010) Karthik Venkatakrishnan et al. CLINICAL PHARMACOKINETICS
- Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism
- (2010) Kuan Gandelman et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Interaction between midazolam and clarithromycin in the elderly
- (2007) Sara K. Quinney et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search